Masayuki Shibasaki

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

Atsuo Tahara, Eiji Kurosaki, Masanori Yokono et al. · European Journal of Pharmacology · 2013 · 305 citations

Obesity, Metabolic Syndrome, Inflammation +10

Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice

Takeyuki Nagashima, Nobuharu Shigematsu, Riyo Maruki et al. · Molecular Pharmacology · 2010 · 272 citations

Prediction of Pediatric Endotracheal Tube Size by Ultrasonography

Masayuki Shibasaki, Yasufumi Nakajima, Sachiyo Ishii et al. · Anesthesiology · 2010 · 231 citations · Full text

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki et al. · European Journal of Pharmacology · 2014 · 190 citations · Full text

Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury

Masayuki Shibasaki, Mika Sasaki, Mayumi Miura et al. · Pain · 2010 · 129 citations

Peripheral Nerve Injury, Pain Medicine, Immunology +20